{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:26Z","timestamp":1790805146404,"version":"4.1.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>\n                    Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2018; 00:000\u2010000).\n                  <\/jats:p>","DOI":"10.1002\/hep.29882","type":"journal-article","created":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T11:49:35Z","timestamp":1521978575000},"page":"1174-1188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":67,"title":["Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis"],"prefix":"10.1097","volume":"68","author":[{"given":"Cyriel Y.","family":"Ponsioen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology & Hepatology,Academic Medical Center,Amsterdam,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[{"name":"College of Health Solutions,Arizona State University,Phoenix,AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Inborn Errors Products,United States Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Dimick\u2010Santos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Inborn Errors Products,United States Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"hep29882-bib-0001-20251105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","year":"2012","journal-title":"JHepatol"},{"key":"hep29882-bib-0002-20251105","first-page":"660","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","year":"2009","journal-title":"Hepatology"},{"key":"hep29882-bib-0003-20251105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"JHepatol"},{"key":"hep29882-bib-0004-20251105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.21685","article-title":"Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep29882-bib-0005-20251105","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population\u2010based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep29882-bib-0006-20251105","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.cgh.2015.05.035","article-title":"Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep29882-bib-0007-20251105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep29882-bib-0008-20251105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population","volume":"51","year":"2002","journal-title":"Gut"},{"key":"hep29882-bib-0009-20251105","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0010-20251105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.crohns.2011.07.015","article-title":"A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease","volume":"6","year":"2012","journal-title":"JCrohns Colitis"},{"key":"hep29882-bib-0011-20251105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13516","article-title":"Patients with large\u2010duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"hep29882-bib-0012-20251105","first-page":"43","article-title":"Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease","volume":"4","year":"2016","journal-title":"Gastroenterol Rep"},{"key":"hep29882-bib-0013-20251105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/lt.22161","article-title":"Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations","volume":"16","year":"2010","journal-title":"Liver Transpl"},{"key":"hep29882-bib-0014-20251105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","year":"2011","journal-title":"Digest Liver Dis"},{"key":"hep29882-bib-0015-20251105","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep29882-bib-0016-20251105","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"hep29882-bib-0017-20251105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"J Hepatol"},{"key":"hep29882-bib-0018-20251105","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","year":"2016","journal-title":"Liver Int"},{"key":"hep29882-bib-0019-20251105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MJT.0b013e3181c9dac6","article-title":"Primary sclerosing cholangitis associated with elevated immunoglobulinG4: clinical characteristics and response to therapy","volume":"18","year":"2011","journal-title":"Am J Ther"},{"key":"hep29882-bib-0020-20251105","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/ibd.22938","article-title":"Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease","volume":"18","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"hep29882-bib-0021-20251105","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2010.235408","article-title":"Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?","volume":"60","year":"2011","journal-title":"Gut"},{"key":"hep29882-bib-0022-20251105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline","volume":"66","year":"2017","journal-title":"JHepatol"},{"key":"hep29882-bib-0023-20251105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","article-title":"Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment","volume":"36","year":"2002","journal-title":"JHepatol"},{"key":"hep29882-bib-0024-20251105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.gie.2009.10.041","article-title":"Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long\u2010term treatment","volume":"71","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"hep29882-bib-0025-20251105","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","article-title":"Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis","volume":"24","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep29882-bib-0026-20251105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","year":"2009","journal-title":"JHepatol"},{"key":"hep29882-bib-0027-20251105","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC\u2010A position statement from the International PSC Study Group","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep29882-bib-0028-20251105","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1007\/s10620-005-2927-8","article-title":"The value of serum CA 19\u20109 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis","volume":"50","year":"2005","journal-title":"Dig Dis Sci"},{"key":"hep29882-bib-0029-20251105","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep29882-bib-0030-20251105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep29882-bib-0031-20251105","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/S0168-8278(16)00171-9","article-title":"Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis: results of a phase II dose finding study","volume":"64","year":"2016","journal-title":"JHepatol"},{"key":"hep29882-bib-0032-20251105","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0168-8278(17)30408-7","article-title":"Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose\u2010ranging, randomized, placebo\u2010controlled trial","volume":"66","year":"2017","journal-title":"JHepatol"},{"key":"hep29882-bib-0033-20251105","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0016-5085(95)90220-1","article-title":"Colchicine treatment of primary sclerosing cholangitis","volume":"108","year":"1995","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0034-20251105","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"hep29882-bib-0035-20251105","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High\u2010dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5\u2010year multicenter, randomized, controlled study","volume":"129","year":"2005","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0036-20251105","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High\u2010dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep29882-bib-0037-20251105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/21678707.2014.935763","article-title":"Clinical trial safety population size: analysis of drug approvals for rare and common indications by FDA Center for Drug Evaluation and Research","volume":"2","year":"2014","journal-title":"Expert Opin Orphan Drugs"},{"key":"hep29882-bib-0038-20251105","first-page":"1633","article-title":"Fatigue in primary sclerosing cholangitis is associated with sympathetic over\u2010activity and increased cardiac output","volume":"35","year":"2014","journal-title":"Liver Int"},{"key":"hep29882-bib-0039-20251105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1055\/s-0030-1255527","article-title":"Validation of a cholangiographic prognostic model in primary sclerosing cholangitis","volume":"42","year":"2010","journal-title":"Endoscopy"},{"key":"hep29882-bib-0040-20251105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta\u2010analysis of diagnostic performance of MR cholangiopancreatography","volume":"256","year":"2010","journal-title":"Radiology"},{"key":"hep29882-bib-0041-20251105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2214\/ajr.179.2.1790399","article-title":"MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography","volume":"179","year":"2002","journal-title":"Am J Roentgenol"},{"key":"hep29882-bib-0042-20251105","first-page":"242","article-title":"Radiologic course of primary sclerosing cholangitis: assessment by three\u2010dimensional magnetic resonance cholangiography and predictive features of progression","volume":"59","year":"2013","journal-title":"Hepatology"},{"key":"hep29882-bib-0043-20251105","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/j.1572-0241.1999.01364.x","article-title":"Four years experience with short term stenting in primary sclerosing cholangitis","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"hep29882-bib-0044-20251105","article-title":"Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis","year":"2017","journal-title":"Gut"},{"key":"hep29882-bib-0045-20251105","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep29882-bib-0046-20251105","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.27715","article-title":"Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep29882-bib-0047-20251105","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jgh.13263","article-title":"Performance of magnetic resonance elastography in primary sclerosing cholangitis","volume":"31","year":"2016","journal-title":"JGastroenterol Hepatol"},{"key":"hep29882-bib-0048-20251105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant\u2010free survival in primary sclerosing cholangitis","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep29882-bib-0049-20251105","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant\u2010free survival in primary sclerosing cholangitis, a multi\u2010centre study","volume":"37","year":"2017","journal-title":"Liver Int"},{"key":"hep29882-bib-0050-20251105","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in utah children: Epidemiology and natural history","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep29882-bib-0051-20251105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cgh.2008.10.019","article-title":"A retrospective single\u2010center review of primary sclerosing cholangitis in children","volume":"7","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep29882-bib-0052-20251105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/jhep.2003.50289","article-title":"Primary sclerosing cholangitis in children: a long\u2010term follow\u2010up study","volume":"38","year":"2003","journal-title":"Hepatology"},{"key":"hep29882-bib-0053-20251105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-3476(94)70253-5","article-title":"Sclerosing cholangitis in children","volume":"124","year":"1994","journal-title":"JPediatr"},{"key":"hep29882-bib-0054-20251105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0009-9120(79)80122-8","article-title":"Predictive values of various liver function tests with respect to the diagnosis of liver disease","volume":"12","year":"1979","journal-title":"Clin Biochem"},{"key":"hep29882-bib-0055-20251105","first-page":"136","article-title":"Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children","volume":"31","year":"2000","journal-title":"JPediatr Gastroenterol Nutr"},{"key":"hep29882-bib-0056-20251105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","article-title":"Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16\u2010year prospective study","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"hep29882-bib-0057-20251105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","article-title":"Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0058-20251105","doi-asserted-by":"crossref","first-page":"e0164224","DOI":"10.1371\/journal.pone.0164224","article-title":"Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in primary sclerosing cholangitis","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep29882-bib-0059-20251105","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1016\/S0168-8278(16)00710-8","article-title":"Liver stiffness measurement by transient elastography for the prediction of fibrosis in patients with primary sclerosing cholangitis in a randomized trial of simtuzumab","volume":"64","year":"2016","journal-title":"JHepatol"},{"key":"hep29882-bib-0060-20251105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.gastro.2014.04.058","article-title":"Transient elastography in primary sclerosing cholangitis\u2014the value as a prognostic factor and limitations","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0061-20251105","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/hep.22577","article-title":"Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep29882-bib-0062-20251105","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ultrasmedbio.2016.04.016","article-title":"Ultrasound and point shear wave elastography in livers of patients with primary sclerosing cholangitis","volume":"42","year":"2016","journal-title":"Ultrasound Med Biol"},{"key":"hep29882-bib-0063-20251105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmri.24250","article-title":"Dynamic gadoxetate\u2010enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis","volume":"39","year":"2014","journal-title":"JMagn Reson Imaging"},{"key":"hep29882-bib-0064-20251105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","article-title":"Phase I clinical evaluation of Gd\u2010EOB\u2010DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging","volume":"195","year":"1995","journal-title":"Radiology"},{"key":"hep29882-bib-0065-20251105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/gutjnl-2016-311452","article-title":"Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis","volume":"65","year":"2016","journal-title":"Gut"},{"key":"hep29882-bib-0066-20251105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","year":"2010","journal-title":"Pathol Int"},{"key":"hep29882-bib-0067-20251105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history, prognostic factors, and surviaval analysis","volume":"10","year":"1989","journal-title":"Hepatology"},{"key":"hep29882-bib-0068-20251105","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/0016-5085(92)91449-E","article-title":"Primary sclerosing cholangitis: refinement and validation of survival models","volume":"103","year":"1992","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0069-20251105","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis","volume":"38","year":"1996","journal-title":"Gut"},{"key":"hep29882-bib-0070-20251105","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0016-5085(91)90673-9","article-title":"Natural history and prognostic variables in primary sclerosing cholangitis","volume":"100","year":"1991","journal-title":"Gastroenterology"},{"key":"hep29882-bib-0071-20251105","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.humpath.2012.09.017","article-title":"Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems","volume":"44","year":"2013","journal-title":"Hum Pathol"},{"key":"hep29882-bib-0072-20251105","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2015.06.008","article-title":"Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis","volume":"63","year":"2015","journal-title":"JHepatol"},{"key":"hep29882-bib-0073-20251105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.28963","article-title":"Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep29882-bib-0074-20251105","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jcp.48.10.933","article-title":"Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis","volume":"48","year":"1995","journal-title":"JClin Pathol"},{"key":"hep29882-bib-0075-20251105","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1111\/j.1572-0241.1999.01543.x","article-title":"Time course of histological progression in PSC","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"hep29882-bib-0076-20251105","first-page":"1","article-title":"Beyond scoring: a modern interpretation of disease progression in chronic liver disease","volume":"62","year":"2013","journal-title":"Gut"},{"key":"hep29882-bib-0077-20251105","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/S0168-8278(16)01221-6","article-title":"Correlations between hepatic morphometric collagen content, histologic fibrosis stage, and serum markers in patients with primary sclerosing cholangitis (PSC)","volume":"64","year":"2016","journal-title":"JHepatol"},{"key":"hep29882-bib-0078-20251105","first-page":"137","article-title":"Evaluating co\u2010primary endpoints collectively in clinical trials","volume":"51","year":"2009","journal-title":"Biomed J"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201809000-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:01:35Z","timestamp":1762376495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201809000-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29882","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"2017-10-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}